Clinical Trial: NCT04947319
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Ono Pharmaceutical Co., Ltd. |
| Information Provided By: | Ono Pharmaceutical Co., Ltd. |
| Last Update Posted: | 2026-03-30 |
Study Overview
Brief Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Official Title
Conditions
Intervention / Treatment
- Drug: Tirabrutinib
- Drug: Tirabrutinib
- Drug: Tirabrutinib
Other Study ID Numbers
- ONO-4059-09
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Ono Pharmaceutical Co., Ltd. |
| Information Provided By: | Ono Pharmaceutical Co., Ltd. |
| Last Update Posted: | 2026-03-30 |
Study Overview
Brief Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Official Title
Conditions
Intervention / Treatment
- Drug: Tirabrutinib
- Drug: Tirabrutinib
- Drug: Tirabrutinib
Other Study ID Numbers
- ONO-4059-09